ENA Confirms Total Benefit-Risk of J&J (JNJ) Vaccine Remains Positive - Bloomberg
- Wall St weighed down by inflation jitters
- AT&T (T) to Merge Media Assets with Discovery (DISCA) in Blockbuster Deal, Valuation Estimated at $150 Billion
- Bitcoin (BTC) Hits 3-Month Lows Before Bouncing as Musk Confirms Tesla Has Not Sold Any BTC
- Morgan Stanley Sees a Path for Amazon.com (AMZN) to Hit $6,000 In the Next 12 Months
- Core-Mark (CORE) Receives Takeover Approach from Performance Food Group (PFGC) - Source
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
ENA Confirms Total Benefit-Risk of J&J (NYSE: JNJ) Vaccine Remains Positive - Bloomberg
- Vaccine Rare Clotting Causal Link Possible
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- J&J cuts vaccine deliveries to EU by half this week - EU source
- Regeneron (REGN), Sanofi (SNY) pivotal data at ATS 2021 show Dupixent significantly reduced asthma attacks and improved lung function in children
- Antengene and Calithera Biosciences (CALA) Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708
Create E-mail Alert Related CategoriesFDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!